Richard S Geary sold $2.6M of IONS
EVP, Chief Development Officer at IONIS PHARMACEUTICALS INC. 34,639 shares at an average of $75.69, traded Nov 5, 2025, filed Nov 7, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.6M at market
- +20Share of holdings soldSold 57% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +11.1%, 3m +17.6%, 6m +2.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000277, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 5, 2025 | MOption exercise Common Stock10b5-1 | +800 | $56.78 | $45k | 60,457 | Nov 7, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stock10b5-1 | -800 | $75.01 | $60k | 59,657 | Nov 7, 2025 |
| Nov 5, 2025 | MOption exercise Common Stock10b5-1 | +801 | $60.89 | $49k | 60,458 | Nov 7, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stock10b5-1 | -801 | $75.01 | $60k | 59,657 | Nov 7, 2025 |
| Nov 6, 2025 | MOption exercise Common Stock10b5-1 | +14,738 | $56.78 | $837k | 74,395 | Nov 7, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stock10b5-1 | -14,738 | $76.10 | $1.1M | 59,657 | Nov 7, 2025 |
| Nov 6, 2025 | MOption exercise Common Stock10b5-1 | +18,300 | $60.89 | $1.1M | 77,957 | Nov 7, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stock10b5-1 | -18,300 | $75.42 | $1.4M | 59,657 | Nov 7, 2025 |
| Nov 5, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -800 | $0.00 | $0 | 14,738 | Nov 7, 2025 |
| Nov 6, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -14,738 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 5, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -801 | $0.00 | $0 | 18,300 | Nov 7, 2025 |
| Nov 6, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -18,300 | $0.00 | $0 | 0 | Nov 7, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | IONSbuy IONIS PHARMACEUTICALS INC | Michael R Hayden director | $1.1M 20,000 shares | +500% | |
| 45Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $1.7M 20,536 shares | -25% | |
| 38Weak | IONIS PHARMACEUTICALS INC | Allene M. Diaz director | $864k 10,111 shares | -73% | |
| 15Weak | IONIS PHARMACEUTICALS INC | Holly B. Kordasiewicz EVP, Chief Development Officer | $31k 362 shares | -2% | |
| 39Weak | IONIS PHARMACEUTICALS INC | Joseph Klein III director | $910k 11,518 shares | -51% | |
| 32Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $452k 5,635 shares | -55% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $2.1M 26,000 shares | -25% | |
| 23Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $246k 3,069 shares | -5% | |
| 43Moderate | IONIS PHARMACEUTICALS INC | Eric Swayze EVP Research | $839k 10,602 shares | -33% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $6.8M 85,637 shares | -33% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.